Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism

British Journal of Pharmacology

Volumn 174, Issue 13, 2017, Pages 2043-2059

  Yeo, Samuel Chao Ming ^a,b   Fenwick, Peter S ^a   Barnes, Peter J ^a   Lin, Hai Shu ^b   Donnelly, Louise E ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; ISORHAPONTIGENIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYPHENOL; PROTEIN KINASE B; RESVERATROL; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; STILBENE DERIVATIVE;

A-549 CELL LINE; AIRWAY EPITHELIUM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; IC50; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; AGED; ANIMAL; BIOAVAILABILITY; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RESPIRATORY SYSTEM; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYSTEM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 85019403671     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13803     Document Type: Article

References (70)

1. Adams M, Pacher T, Greger H, Bauer R (2005). Inhibition of leukotriene biosynthesis by stilbenoids from Stemona species. J Nat Prod 68: 83–85.
2. Adhami VM, Afaq F, Ahmad N (2003). Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia (New York, NY) 5: 74–82.
3. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
5. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA (1996). Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 93: 5699–5704.
6. Barnes PJ (2009). The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 41: 631–638.
7. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493–506.
8. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P et al. (2013). Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 20: 1323–1331.
9. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP et al. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16: 1246–1252.
10. Brognard J, Sierecki E, Gao T, Newton AC (2007). PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917–931.
11. Caelles C, Gonzalez-Sancho JM, Munoz A (1997). Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11: 3351–3364.
12. Chen W, Yeo SC, Elhennawy MG, Xiang X, Lin HS (2015). Determination of naturally occurring resveratrol analog trans-4,4′-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Anal Bioanal Chem 407: 5793–5801.
13. Chen W, Yeo SCM, Elhennawy MGAA, Lin H-S (2016). Oxyresveratrol: a bioavailable dietary polyphenol. J Funct Foods 22: 122–131.
14. Choi KH, Kim JE, Song NR, Son JE, Hwang MK, Byun S et al. (2010). Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 85: 836–844.
15. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE et al. (2003a). Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58: 942–946.
16. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell REK, Donnelly LE et al. (2003b). Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 24–31.
17. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
18. Das S, Lin HS, Ho PC, Ng KY (2008). The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 25: 2593–2600.
19. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, Ito K et al. (2004). Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 287: L774–L783.
20. Eda H, Burnette BL, Shimada H, Hope HR, Monahan JB (2011). Interleukin-1beta-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4. Cell Biol Int 35: 355–358.
21. Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J et al. (2013). Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther 12: 1492–1503.
22. Fenwick PS, Macedo P, Kilty IC, Barnes PJ, Donnelly LE (2015). Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells. PLoS One 10: e0128757.
23. Fernandez-Marin MI, Guerrero RF, Garcia-Parrilla MC, Puertas B, Richard T, Rodriguez-Werner MA et al. (2012). Isorhapontigenin: a novel bioactive stilbene from wine grapes. Food Chem 135: 1353–1359.
24. Frojdo S, Cozzone D, Vidal H, Pirola L (2007). Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 406: 511–518.
25. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D (2013). Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J 42: 28–41.
26. Ganesan S, Unger BL, Comstock AT, Angel KA, Mancuso P, Martinez FJ et al. (2013). Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A. Thorax 68: 131–141.
27. Gao G, Chen L, Li J, Zhang D, Fang Y, Huang H et al. (2014). Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA stability. Oncotarget 5: 2664–2677.
28. Gao W, Li L, Wang Y, Zhang S, Adcock IM, Barnes PJ et al. (2015). Bronchial epithelial cells: the key effector cells in the pathogenesis of chronic obstructive pulmonary disease? Respirology 20: 722–729.
29. Ge Q, Moir LM, Black JL, Oliver BG, Burgess JK (2010). TGFbeta1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells: the role of Smad2/3. J Cell Physiol 225: 846–854.
30. GOLD (2016). Global strategy for the diagnosis, management and prevention of COPDGlobal initiative for chronic obstructive lung disease.
31. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P (1988). c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55: 917–924.
32. Hasiah AH, Ghazali AR, Weber JF, Velu S, Thomas NF, Inayat Hussain SH (2011). Cytotoxic and antioxidant effects of methoxylated stilbene analogues on HepG2 hepatoma and Chang liver cells: Implications for structure activity relationship. Hum Exp Toxicol 30: 138–144.
33. Highland KB, Strange C, Heffner JE (2003). Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis Annals of internal medicine 138: 969–973.
34. Hoesel B, Schmid JA (2013). The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12: 86.
35. Hogg JC (2004). Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. The Lancet 364: 709–721.
36. Huang H, Tindall DJ (2011). Regulation of FoxO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 1813: 1961–1964.
37. Ito K, Barnes PJ (2009). COPD as a disease of accelerated lung aging. Chest 135: 173–180.
38. Ito K, Caramori G, Adcock IM (2007). Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321: 1–8.
39. Jang BC, Lim KJ, Suh MH, Park JG, Suh SI (2007). Dexamethasone suppresses interleukin-1beta-induced human beta-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, and NF-kappaB transcriptional factor in A549 cells. FEMS Immunol Med Microbiol 51: 171–184.
40. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L (2003). IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17: 2115–2117.
41. Kageura T, Matsuda H, Morikawa T, Toguchida I, Harima S, Oda M et al. (2001). Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: structural requirements of stilbenes for the activity. Bioorg Med Chem 9: 1887–1893.
42. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
43. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I (2008). Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 294: L478–L488.
44. Kops GJPL, Dansen TB, Polderman PE, Saarloos I, Wirtz KWA, Coffer PJ et al. (2002). Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316–321.
45. Lee I-T, Yang C-M (2013). Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm 2013: 12.
46. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM et al. (2005). Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38: 243–257.
47. Lin CH, Cheng HW, Ma HP, Wu CH, Hong CY, Chen BC (2011). Thrombin induces NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells by a Rac1-dependent PI3K/Akt pathway. J Biol Chem 286: 10483–10494.
48. Liu Y, Liu G (2004). Isorhapontigenin and resveratrol suppress oxLDL-induced proliferation and activation of ERK1/2 mitogen-activated protein kinases of bovine aortic smooth muscle cells. Biochem Pharmacol 67: 777–785.
49. Liu PL, Tsai JR, Charles AL, Hwang JJ, Chou SH, Ping YH et al. (2010). Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol Nutr Food Res 54 (Suppl 2): S196–S204.
50. Machuca C, Mendoza-Milla C, Córdova E, Mejía S, Covarrubias L, Ventura J et al. (2006). Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol 7: 1–12.
51. Mannino DM, Buist AS (2007). Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765–773.
52. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP (2002). Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369–373.
53. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
54. Mitani A, Ito K, Vuppusetty C, Barnes PJ, Mercado N (2015). Restoration of corticosteroid sensitivity in chronic obstructive pulmonary disease by inhibition of mammalian target of rapamycin. Am J Respir Crit Care Med 193: 143–153.
55. Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G et al. (2012). Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 303: L929–L938.
56. Musti AM, Treier M, Bohmann D (1997). Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275: 400–402.
57. Newton R, Hart LA, Stevens DA, Bergmann M, Donnelly LE, Adcock IM et al. (1998). Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. European journal of biochemistry / FEBS 254: 81–89.
58. Patel IS, Roberts NJ, Lloyd-Owen SJ, Sapsford RJ, Wedzicha JA (2003). Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 22: 94–99.
59. Shah S, King EM, Chandrasekhar A, Newton R (2014). Roles for the mitogen-activated protein kinase (MAPK) phosphatase, DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone. J Biol Chem 289: 13667–13679.
60. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
61. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29–39.
62. Tak PP, Firestein GS (2001). NF-κB: a key role in inflammatory diseases. J Clin Invest 107: 7–11.
63. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T et al. (2010). Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182: 897–904.
64. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ et al. (2008). Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 324: 306–312.
65. Vos T, Barber RM, Bell B (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet London, England 386: 743–800.
66. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377–1382.
67. Wirtz HR, Schmidt M (1996). Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J 9: 24–32.
68. Yao CS, Lin M, Liu X, Wang YH (2003). Stilbenes from Gnetum cleistostachyum. Acta Chimica Sinica 61: 1331–1334.
69. Yeo SC, Ho PC, Lin HS (2013). Pharmacokinetics of pterostilbene in Sprague–Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res 57: 1015–1025.
70. Zhong H, May MJ, Jimi E, Ghosh S (2002). The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9: 625–636.